Market Research Reports and Industry Reports
instagram takipci kasma instagram takipci kasma atasehir escort maltepe escort kurtkoy escort maltepe escort alanya escort antalya escort konya escort tuzla escort pendik escort bostanci escort atasehir escort kadikoy escort kurtkoy escort tuzla escort erenkoy escort beykoz escort umraniye escort

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 2017

Summary

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report 5-Hydroxytryptamine Receptor 7 - Pipeline Review, H2 2017, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Genetic Disorders which include indications Psychiatric Disorders, Bipolar Disorder (Manic Depression), Major Depressive Disorder, Schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Anxiety Disorders, Cognitive Disorders, Fragile X Syndrome, Inflammatory Pain, Migraine, Neuropathic Pain, Pervasive Developmental Disorder (PDD), Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Social Anxiety Disorders (SAD) and Tourette Syndrome.

Furthermore, this report also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
- The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Overview
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Companies Involved in Therapeutics Development
Adamed Sp z oo
Astellas Pharma Inc
Braeburn Pharmaceuticals Inc
H. Lundbeck AS
Johnson & Johnson
Reviva Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Drug Profiles
ADN-1184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-3662 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-9242 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDD-028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-18038683 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lurasidone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-5063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Alpha 2 Adrenergic Receptor and Antagonize 5-HT7 and 5-HT5A Receptors for Psychiatric Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for Migraine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vortioxetine hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones
Featured News & Press Releases
Dec 04, 2017: Lundbecks Brintellix approved in China
Oct 27, 2017: Sunovion Presents Data from Phase 3 Studies of Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression
Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension
Sep 14, 2017: Sunovion to Present Data on LATUDA at the 2017 Psych Congress
Jul 21, 2017: Sunovions Latuda (lurasidone HCI) Receives Health Canada Approval to Treat Adolescents with Schizophrenia
Jun 30, 2017: Sunovion Announces FDA Acceptance for Review of Supplemental New Drug Application for Latuda for the Treatment of Bipolar Depression in Children and Adolescents
Jun 23, 2017: Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix (vortioxetine) sNDA
Jun 23, 2017: Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix sNDA
Jun 09, 2017: Sumitomo Dainippon Pharma Announces Topline Results from a Phase 3 Study of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Bipolar l Depression
May 22, 2017: Sunovion Announces Positive Results from Study Evaluating Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression at Annual American Psychiatric Association Meeting
May 16, 2017: Sunovion to Present Data on Latuda (lurasidone HCl) at Annual American Psychiatric Association Meeting
Mar 31, 2017: Sunovion to Present Data on LATUDA (lurasidone HCI) at the 25th European Congress of Psychiatry
Feb 27, 2017: Sunovion Announces Positive Topline Results from Study Evaluating Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression
Jan 28, 2017: Sunovions Latuda (lurasidone HCl) Receives FDA Approval to Treat Adolescents with Schizophrenia
Dec 02, 2016: Sunovion to Present Data on Latuda (lurasidone HCl) at the 55th Annual Meeting of the American College of Neuropsychopharmacology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Adamed Sp z oo, H2 2017
Pipeline by Astellas Pharma Inc, H2 2017
Pipeline by Braeburn Pharmaceuticals Inc, H2 2017
Pipeline by H. Lundbeck AS, H2 2017
Pipeline by Johnson & Johnson, H2 2017
Pipeline by Reviva Pharmaceuticals Inc, H2 2017
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017

List Of Figures


Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 2017

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 20175-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7

USD 3500View Report

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H2 2017

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H2 2017According to the recently published report 5-Hydroxytryptamine Receptor 2B - Pipeline Review, H2 2017; 5-Hydroxytryptamine

USD 3500View Report

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Pipeline Review, H2 2017

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Pipeline Review, H2 2017Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) pipeline Target constitutes close to 7 molecules. Out

USD 3500View Report

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H2 2017

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Pipeline Review, H2 2017According to the recently published report 5-Hydroxytryptamine Receptor 2B - Pipeline Review, H2 2017; 5-Hydroxytryptamine

USD 3500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 3500
  • Site Licence    USD 7000
  • Enterprise Wide Licence    USD 10500
$ 3500

Reports Details

Published Date : Dec 2017
No. of Pages :67
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
Copyright © 2008 - 2018 Aarkstore.com | All rights reserved.